AMPK activation: A therapeutic target for type 2 diabetes?

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 241-253

  Coughlan, Kimberly A ^a   Valentine, Rudy J ^a   Ruderman, Neil B ^a   Saha, Asish K ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenosine monophosphate activated protein kinase; Drug therapy; Insulin resistance; Type 2 diabetes

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACETYLSALICYLIC ACID; ADIPONECTIN; BERBERINE; BUFORMIN; C 24; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; INTERLEUKIN 6; LEPTIN; LIRAGLUTIDE; METFORMIN; PHENFORMIN; PIOGLITAZONE; PLANT EXTRACT; PROGUANIL; PT 1; RESVERATROL; ROOIBOS EXTRACT; ROSIGLITAZONE; SALICYLIC ACID; SALSALATE; THIOCTIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ASPALATHUS; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; EXERCISE; FATTY LIVER; HUMAN; HYPOGLYCEMIA; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; RISK REDUCTION; ROOIBOS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84903273250     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S43731     Document Type: Review

References (176)

1. International Diabetes Federation. Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013.
2. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov. 2004;3(4): 340-351.
3. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 2013;123(7):2764-2772.
4. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. Nutrient excess in AMPK downregulation and insulin resistance. Journal of Endocrinology, Diabetes and Obesity. 2013;1(1):1008.
5. O'Neill HM. AMPK and exercise: glucose uptake and insulin sensitivity. Diabetes Metab J. 2013;37(1):1-21.
6. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev. 2009;89(3):1025-1078.
7. Birnbaum MJ. Activating AMP-activated protein kinase without AMP. Mol Cell. 2005;19(3):289-290.
8. Lizcano JM, Göransson O, Toth R, etal. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004;23(4):833-843.
9. Woods A, Johnstone SR, Dickerson K, etal. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 2003;13(22):2004-2008.
10. Hawley SA, Pan DA, Mustard KJ, etal. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005;2(1):9-19.
11. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem. 2006;281(35):25336-25343.
12. Horman S, Vertommen D, Heath R, etal. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem. 2006;281(9):5335-5340.
13. Ning J, Xi G, Clemmons DR. Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology. 2011; 152(8):3143-3154.
14. Hurley RL, Barré LK, Wood SD, etal. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem. 2006;281(48):36662-36672.
15. Pulinilkunnil T, He H, Kong D, etal. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J Biol Chem. 2011;286(11):8798-8809.
16. Berggreen C, Gormand A, Omar B, Degerman E, Göransson O. Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes. Am J Physiol Endocrinol Metab. 2009;296(4): E635-E646.
17. Dagon Y, Hur E, Zheng B, Wellenstein K, Cantley LC, Kahn BB. p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake. Cell Metab. 2012;16(1):104-112.
18. Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie NR, Hardie DG. Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells. Biochem J. 2014;459(2): 275-287.
19. Xiao B, Heath R, Saiu P, etal. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature. 2007;449(7161): 496-500.
20. Chen L, Wang J, Zhang YY, etal. AMP-activated protein kinase undergoes nucleotide-dependent conformational changes. Nat Struct Mol Biol. 2012;19(7):716-718.
21. Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG. 5′-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem. 1995;270(45):27186-27191.
22. Davies SP, Helps NR, Cohen PT, Hardie DG. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett. 1995;377(3):421-425.
23. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D. Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem. 2006;281(43):32207-32216.
24. Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 2013;18(4): 556-566.
25. Xiao B, Sanders MJ, Underwood E, etal. Structure of mammalian AMPK and its regulation by ADP. Nature. 2011;472(7342):230-233.
26. Oakhill JS, Steel R, Chen ZP, etal. AMPK is a direct adenylate charge-regulated protein kinase. Science. 2011;332(6036):1433-1435.
27. Munday MR, Campbell DG, Carling D, Hardie DG. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur J Biochem. 1988;175(2):331-338.
28. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577-590.
29. Clarke PR, Hardie DG. Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J. 1990;9(8):2439-2446.
30. Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A. 2007;104(29): 12017-12022.
31. Zong H, Ren JM, Young LH, etal. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A. 2002;99(25):15983-15987.
32. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53(12):2490-2514.
33. Minokoshi Y, Alquier T, Furukawa N, etal. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428(6982):569-574.
34. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes. 2006;55(8):2277-2285.
35. Xu XJ, Gauthier MS, Hess DT, etal. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J Lipid Res. 2012;53(4): 792-801.
36. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010;1804(3):581-591.
37. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J. 2009;418(2): 261-275.
38. Winder WW, Hardie DG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol. 1996;270(2 Pt 1):E299-E304.
39. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 1998;47(8): 1369-1373.
40. Hutber CA, Hardie DG, Winder WW. Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase. Am J Physiol. 1997;272(2 Pt 1):E262-E266.
41. Vavvas D, Apazidis A, Saha AK, etal. Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. J Biol Chem. 1997;272(20):13255-13261.
42. Park H, Kaushik VK, Constant S, etal. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem. 2002;277(36):32571-32577.
43. Wojtaszewski JF, Nielsen P, Hansen BF, Richter EA, Kiens B. Isoform-specific and exercise intensity-dependent activation of 5′-AMP-activated protein kinase in human skeletal muscle. J Physiol. 2000;528 Pt 1:221-226.
44. Chen ZP, Stephens TJ, Murthy S, etal. Effect of exercise intensity on skeletal muscle AMPK signaling in humans. Diabetes. 2003;52(9): 2205-2212.
45. Fujii N, Hayashi T, Hirshman MF, etal. Exercise induces isoform-specific increase in 5′AMP-activated protein kinase activity in human skeletal muscle. Biochem Biophys Res Commun. 2000;273(3): 1150-1155.
46. Sahlin K, Tonkonogi M, Söderlund K. Energy supply and muscle fatigue in humans. Acta Physiol Scand. 1998;162(3):261-266.
47. O'Neill HM, Maarbjerg SJ, Crane JD, etal. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci U S A. 2011;108(38): 16092-16097.
48. Lantier L, Fentz J, Mounier R, etal. AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity. FASEB J. Epub March 20, 2014.
49. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229(2): 558-565.
50. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 1994;353(1):33-36.
51. Song XM, Fiedler M, Galuska D, etal. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia. 2002;45(1): 56-65.
52. Bergeron R, Previs SF, Cline GW, etal. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes. 2001;50(5): 1076-1082.
53. Buhl ES, Jessen N, Schmitz O, etal. Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes. 2001;50(1): 12-17.
54. Iglesias MA, Ye JM, Frangioudakis G, etal. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes. 2002;51(10): 2886-2894.
55. Narkar VA, Downes M, Yu RT, etal. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405-415.
56. Thomas A, Beuck S, Eickhoff JC, etal. Quantification of urinary AICAR concentrations as a matter of doping controls. Anal Bioanal Chem. 2010;396(8):2899-2908.
57. Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes. 1991;40(10):1259-1266.
58. Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, Allard MF. 5-Aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol. 2003;284(4):R936-R944.
59. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer. 2007;6:46.
60. Leclerc GM, Leclerc GJ, Fu G, Barredo JC. AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia. J Mol Signal. 2010;5:15.
61. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res. 1993;27(1): 43-47.
62. Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA. 1997;277(4):325-332.
63. Gomez-Galeno JE, Dang Q, Nguyen TH, etal. A potent and selective AMPK activator that inhibits de novo lipogenesis. ACS Med Chem Lett. 2010;1:478-482.
64. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9): 1898-1906.
65. Nathan DM, Buse JB, Davidson MB, etal; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52(1): 17-30.
66. Inzucchi SE, Bergenstal RM, Buse JB, etal. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596.
67. Rodbard HW, Jellinger PS, Davidson JA, etal. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
68. Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108(8): 1105-1107.
69. Bailey CJ, Day C. Metformin: its botanical background. Practical Diabetes International. 2004;21(3):115-117.
70. Mehnert H. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S259-S264.
71. Srinivasan B, Taub N, Khunti K, Davies M. Diabetes: glycaemic control in type 2. Clin Evid (Online). 2008;2008. pii: 0609.
72. Haffner S, Temprosa M, Crandall J, etal; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54(5):1566-1572.
73. Buzzai M, Jones RG, Amaravadi RK, etal. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745-6752.
74. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-1305.
75. Zhou G, Myers R, Li Y, etal. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8): 1167-1174.
76. Shaw RJ, Lamia KA, Vasquez D, etal. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642-1646.
77. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3: 607-614.
78. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002;51(8): 2420-2425.
79. Hawley SA, Ross FA, Chevtzoff C, etal. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010;11(6):554-565.
80. Turban S, Stretton C, Drouin O, etal. Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. J Biol Chem. 2012;287(24):20088-20099.
81. Foretz M, Hébrard S, Leclerc J, etal. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7): 2355-2369.
82. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256-260.
83. Fullerton MD, Galic S, Marcinko K, etal. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013;19(12):1649-1654.
84. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002;277(28):25226-25232.
85. LeBrasseur NK, Kelly M, Tsao TS, etal. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab. 2006;291(1):E175-E181.
86. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun. 2004;314(2):580-585.
87. Brunmair B, Staniek K, Gras F, etal. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes. 2004;53(4): 1052-1059.
88. Suzuki H, Eguchi S. Adiponectin versus angiotensin II: Key pathological role of their misbalance. Kidney Int. 2006;70(10):1678-1679.
89. Kubota N, Terauchi Y, Kubota T, etal. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem. 2006;281(13):8748-8755.
90. Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13(3):329-341.
91. He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol. 2014;35(3): 2095-2102.
92. Home PD, Pocock SJ, Beck-Nielsen H, etal; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 2007;357(1):28-38.
93. Hwang JI, Yun S, Moon MJ, Park CR, Seong JY. Evolution of GLP1 and GLP1 receptor. J Mol Endocrinol. Epub March 5, 2014.
94. Baggio LL, Drucker DJ. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treat Endocrinol. 2002;1:117-125.
95. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047-2058.
96. Svegliati-Baroni G, Saccomanno S, Rychlicki C, etal. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31(9):1285-1297.
97. Lee J, Hong SW, Chae SW, etal. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One. 2012;7(2):e31394.
98. Cool B, Zinker B, Chiou W, etal. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3(6):403-416.
99. Göransson O, McBride A, Hawley SA, etal. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem. 2007;282(45):32549-32560.
100. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem. 2007;282(45):32539-32548.
101. Xiao B, Sanders MJ, Carmena D, etal. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017.
102. Scott JW, van Denderen BJ, Jorgensen SB, etal. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol. 2008;15(11):1220-1230.
103. Moreno D, Knecht E, Viollet B, Sanz P. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett. 2008;582(17):2650-2654.
104. Reymond P, Farmer EE. Jasmonate and salicylate as global signals for defense gene expression. Curr Opin Plant Biol. 1998;1(5): 404-411.
105. Jeffreys D. Aspirin: The Remarkable Story of a Wonder Drug. London, UK: Bloomsbury Publishing; 2004.
106. Miners JO, Grgurinovich N, Whitehead AG, Robson RA, Birkett DJ. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol. 1986;22(2):135-142.
107. Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U S A. 1987;84(5):1417-1420.
108. Hawley SA, Fullerton MD, Ross FA, etal. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336(6083):918-922.
109. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289-294.
110. Goldfine AB, Conlin PR, Halperin F, etal. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56(4):714-723.
111. Pang T, Zhang ZS, Gu M, etal. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem. 2008;283(23):16051-16060.
112. Li YY, Yu LF, Zhang LN, etal. Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice. Toxicol Appl Pharmacol. 2013;273(2):325-334.
113. Yu LF, Li YY, Su MB, etal. Development of novel alkene oxindole derivatives as orally efficacious AMP-activated protein kinase activators. ACS Med Chem Lett. 2013;4(5):475-480.
114. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
115. Howitz KT, Bitterman KJ, Cohen HY, etal. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-196.
116. Um JH, Park SJ, Kang H, etal. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59(3):554-563.
117. Hou X, Xu S, Maitland-Toolan KA, etal. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem. 2008;283(29):20015-20026.
118. Zang M, Xu S, Maitland-Toolan KA, etal. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006;55(8):2180-2191.
119. Baur JA, Pearson KJ, Price NL, etal. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117): 337-342.
120. Park CE, Kim MJ, Lee JH, etal. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med. 2007;39(2):222-229.
121. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007;104(17):7217-7222.
122. Gledhill JR, Montgomery MG, Leslie AG, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci U S A. 2007;104(34):13632-13637.
123. Cohen HY, Miller C, Bitterman KJ, et al. Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase. Science. 2004;305(5682):390-392.
124. Ruderman NB, Xu XJ, Nelson L, etal. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. 2010;298(4):E751-E760.
125. 12 muscle cells by rooibos (Aspalathus linearis). Phytomedicine. 2013;20(10):813-819.
126. Beltrán-Debón R, Rull A, Rodríguez-Sanabria F, etal. Continuous administration of polyphenols from aqueous rooibos (Aspalathus linearis) extract ameliorates dietary-induced metabolic disturbances in hyperlipidemic mice. Phytomedicine. 2011;18(5):414-424.
127. Son MJ, Minakawa M, Miura Y, Yagasaki K. Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice. Eur J Nutr. 2013;52(6):1607-1619.
128. Lee YS, Kim WS, Kim KH, etal. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8): 2256-2264.
129. Kong W, Wei J, Abidi P, etal. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351.
130. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717.
131. Cheng Z, Pang T, Gu M, etal. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta. 2006;1760(11):1682-1689.
132. Brusq JM, Ancellin N, Grondin P, etal. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 2006;47(6): 1281-1288.
133. Kim SH, Shin EJ, Kim ED, Bayaraa T, Frost SC, Hyun CK. Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes. Biol Pharm Bull. 2007;30(11):2120-2125.
134. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem. 2009;24(5):1061-1066.
135. Sarna LK, Wu N, Hwang SY, Siow YL, Karmin O Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages. Can J Physiol Pharmacol. 2010;88(3):369-378.
136. Turner N, Li JY, Gosby A, etal. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57(5):1414-1418.
137. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294(1):E148-E156.
138. Choi BH, Kim YH, Ahn IS, Ha JH, Byun JM, Do MS. The inhibition of inflammatory molecule expression on 3T3-L1 adipocytes by berberine is not mediated by leptin signaling. Nutr Res Pract. 2009;3(2):84-88.
139. Lee WJ, Song KH, Koh EH, etal. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005;332(3):885-891.
140. Saha AK, Xu XJ, Lawson E, etal. Downregulation of AMPK accompanies leucine-and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes. 2010;59(10):2426-2434.
141. Lee Y, Naseem RH, Park BH, etal. Alpha-lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice. Biochem Biophys Res Commun. 2006;344(1):446-452.
142. Lee WJ, Lee IK, Kim HS, etal. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol. 2005;25(12):2488-2494.
143. Kim MS, Park JY, Namkoong C, etal. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med. 2004;10(7):727-733.
144. Park KG, Min AK, Koh EH, etal. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology. 2008;48(5):1477-1486.
145. Targonsky ED, Dai F, Koshkin V, etal. alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia. 2006;49(7):1587-1598.
146. Shen QW, Zhu MJ, Tong J, Ren J, Du M. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am J Physiol Cell Physiol. 2007;293(4):C1395-C1403.
147. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46 Suppl 2:S62-S66.
148. van Dam PS. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2002;18(3):176-184.
149. Tartaglia LA, Dembski M, Weng X, etal. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995;83(7):1263-1271.
150. Minokoshi Y, Kim YB, Peroni OD, etal. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339-343.
151. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Mol Cell Biol. 2007;27(12):4317-4327.
152. Tanaka T, Masuzaki H, Yasue S, etal. Central melanocortin signaling restores skeletal muscle AMP-activated protein kinase phosphorylation in mice fed a high-fat diet. Cell Metab. 2007;5(5):395-402.
153. Andersson U, Filipsson K, Abbott CR, etal. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem. 2004;279(13):12005-12008.
154. Yang Y, Atasoy D, Su HH, Sternson SM. Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop. Cell. 2011;146(6):992-1003.
155. Richards AA, Stephens T, Charlton HK, etal. Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol. 2006;20(7): 1673-1687.
156. Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis. 2014;233(2):721-728.
157. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18): 10697-10703.
158. Yamauchi T, Nio Y, Maki T, etal. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-339.
159. Mao X, Kikani CK, Riojas RA, etal. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8(5):516-523.
160. Hada Y, Yamauchi T, Waki H, etal. Selective purification and characterization of adiponectin multimer species from human plasma. Biochem Biophys Res Commun. 2007;356(2):487-493.
161. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 2001;108(12):1875-1881.
162. Fruebis J, Tsao TS, Javorschi S, etal. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98(4):2005-2010.
163. Masaki T, Chiba S, Yasuda T, etal. Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. Diabetes. 2003;52(9):2266-2273.
164. Ouchi N, Kihara S, Arita Y, etal. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103(8):1057-1063.
165. Yamauchi T, Kamon J, Waki H, etal. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278(4):2461-2468.
166. Kubota N, Yano W, Kubota T, etal. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007;6(1):55-68.
167. Ruderman NB, Keller C, Richard AM, etal. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes. 2006;55 Suppl 2:S48-S54.
168. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4):1379-1406.
169. Kelly M, Gauthier MS, Saha AK, Ruderman NB. Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes. 2009;58(9):1953-1960.
170. Kelly M, Keller C, Avilucea PR, etal. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun. 2004;320(2):449-454.
171. Carey AL, Steinberg GR, Macaulay SL, etal. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55(10):2688-2697.
172. Geiger PC, Hancock C, Wright DC, Han DH, Holloszy JO. IL-6 increases muscle insulin sensitivity only at superphysiological levels. Am J Physiol Endocrinol Metab. 2007;292(6):E1842-E1846.
173. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
174. Drummond MJ, Dreyer HC, Fry CS, Glynn EL, Rasmussen BB. Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. J Appl Physiol. 2009;106(4):1374-1384.
175. McKiernan SH, Colman RJ, Lopez M, etal. Caloric restriction delays aging-induced cellular phenotypes in rhesus monkey skeletal muscle. Exp Gerontol. 2011;46(1):23-29.
176. Mercken EM, Crosby SD, Lamming DW, etal. Calorie restriction in humans inhibits the PI3K/AKT pathway and induces a younger transcription profile. Aging Cell. 2013;12(4):645-651.